Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban: review decision - May 2015
Review of NICE Technology Appraisal Guidance No.261; Rivaroxaban for the treatment and secondary prevention of venous thromboembolism, and No.287; Rivaroxaban for the treatment of acute symptomatic pulmonary embolism with or without symptomatic DVT and the prevention of recurrent VTE
Proposal to move the existing guidance to the static list
The planned date for review of the above guidance is May 2015.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has been identified that suggests that an update of either TA261 or TA287 is required at this time.
Consequently we propose that both TA261 and TA287 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
This page was last updated: 11 May 2015